Fluzoparib

Small molecule

Also known as SHR-3162

Phase 3underway

Evidence outlook · registrational

Metastatic Castration-Resistant Prostate Cancer: registrational readout pending

Its supporting mid-stage studies have completed. Registrational readout expected around 2026-12-31.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (12)
Metastatic Castration-Resistant Prostate Cancer
Other / comorbidity
NCT06954584 · Tongji Hospital
2025-05-27 – 2032-03-01 · Ovarian Cancer
What this study did
NCT05891093 · Fudan University
2023-06-01 – 2031-05-31 · Breast Cancer
What this study did
NCT06255392 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-06-12 – 2031-03 · Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer
What this study did
NCT06612814 · Zhimin Shao
2024-09-01 – 2028-04-30 · Breast Cancer Metastatic
What this study did
NCT06913777 · Fudan University
2025-04-08 – 2027-04-15 · Neoadjuvant Therapy
What this study did
NCT06188455 · The First Affiliated Hospital of Xiamen University
2024-12-01 – 2026-12-01 · Ovarian Cancer
What this study did
NCT06539091 · Anhui Provincial Hospital
2024-10-01 – 2026-10-01 · Epithelial Ovarian Cancer, Efficacy, Safety, Bone Mineral Density, Tolerability
What this study did
NCT04296370 · Jiangsu HengRui Medicine Co., Ltd.
2020-07-13 – 2025-06-30 · Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation
What this study did
NCT03863860 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-30 – 2025-06-19 · Ovarian Cancer
What this study did
NCT04229615 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-02 – 2024-04-01 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT04300114 · Jiangsu HengRui Medicine Co., Ltd.
2020-08-19 – 2022-02-18 · Metastatic Pancreatic Cancer
What this study did
Phase 2 (51)
Metastatic Castration-Resistant Prostate Cancer
NCT06971211 · Jianbin Bi
2024-11-27 – 2028-04-30 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT04869488 · Jiangsu HengRui Medicine Co., Ltd.
2021-07-19 – 2023-02-14 · Metastatic Castration Resistant Prostate Cancer
What this study did
Other / comorbidity
NCT07353437 · Fudan University
2026-03-31 – 2032-12-31 · Breast Cancer
What this study did
NCT07647653 · Shandong University
2026-06-30 – 2031-02-28 · Ovarian Cancer
What this study did
NCT07382713 · Jinhua Zhou
2026-02-28 – 2030-12-31 · Ovarian Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07752550 · Harbin Medical University
2026-07-30 – 2029-07-30 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT05761470 · Ying Lin
2022-05-06 – 2028-12-31 · Her-2 Negative Breast Cancer, HRR Gene Mutation
What this study did
NCT06254066 · Zhejiang Cancer Hospital
2024-04-16 – 2028-12-31 · Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer, HRD Positive Advanced Breast Cancer
What this study did
NCT05894018 · Fujun Zhang
2023-06-29 – 2028-12-31 · Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase Inhibitors
What this study did
NCT05576389 · Peking University People's Hospital
2022-10-01 – 2028-12-31 · Germline BRCA-mutated HER2-negative Breast Cancer
What this study did
NCT06735326 · Qilu Hospital of Shandong University
2024-11-27 – 2028-10-01 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT07033819 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-06-25 – 2028-06-01 · Ovarian Cancer
What this study did
NCT06446206 · The First Hospital of Jilin University
2024-06 – 2028-06 · Platinum-sensitive Relapsed Ovarian Cancer
What this study did
NCT06827717 · Sun Yat-sen University
2025-04-15 – 2028-02 · Ewing Sarcoma
What this study did
NCT05656131 · wang shusen
2022-11-23 – 2027-12-31 · Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer
What this study did
NCT05753826 · Fujian Cancer Hospital
2023-08-01 – 2027-12-31 · Ovarian Neoplasms, Ovarian Diseases
What this study did
NCT07321015 · Tianjin Medical University Cancer Institute and Hospital
2026-01-20 – 2027-11-30 · Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or Not
What this study did
NCT06063070 · Sun Yat-sen University
2023-10-18 – 2027-10-30 · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, High Grade Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian-tube Cancer
What this study did
NCT05759546 · Fudan University
2023-02-01 – 2027-06-01 · Breast Cancer Metastatic
What this study did
NCT06413992 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-05-10 – 2027-06-01 · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic
What this study did
NCT06552858 · Fudan University
2024-09-01 – 2027-01-31 · Ovarian Cancer
What this study did
NCT06081595 · Jin Li
2023-10-30 – 2026-12-30 · Relapsed Ovarian Cancer
What this study did
NCT06074692 · Ruijin Hospital
2023-06-01 – 2026-12-30 · Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone
What this study did
NCT05594095 · Fudan University
2022-12-30 – 2026-12-01 · Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
NCT05479487 · Xiaohua Wu MD
2022-08-01 – 2026-09-01 · Relapsed Ovarian Cancer
What this study did
NCT06561022 · Fudan University
2024-08-21 – 2026-06-30 · Breast Cancer
What this study did
NCT06516445 · Huazhong University of Science and Technology
2023-06-28 – 2026-06-28 · Colorectal Cancer
What this study did
NCT05834582 · The First Affiliated Hospital with Nanjing Medical University
2023-04-08 – 2026-06-01 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT06055166 · Chongqing University Cancer Hospital
2023-11-01 – 2026-05-31 · PARP Inhibitor for Esophageal Squamous Cell Carcinoma
What this study did
NCT06541314 · Qilu Hospital of Shandong University
2024-06-18 – 2026-05-31 · Ovarian Cancer
What this study did
NCT07162051 · Xijing Hospital
2023-03-03 – 2026-03-15 · HR+/HER2- Early Breast Cancer
What this study did
NCT06161272 · Guangxi Medical University
2023-12-10 – 2026-01-10 · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
What this study did
NCT04978012 · Fudan University
2021-07-25 – 2025-12-31 · Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
What this study did
NCT05952128 · Sun Yat-sen University
2023-07-01 – 2025-12-01 · Sarcoma
What this study did
NCT05932264 · Sun Yat-sen University
2023-07 – 2025-12 · NSCLC, Non-small Cell Lung Cancer
What this study did
NCT05349409 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-06-09 – 2025-05-31 · Advanced Solid Tumors
What this study did
NCT04355858 · Fudan University
2020-05-01 – 2025-04-01 · Breast Cancer, Metastatic Cancer
What this study did
NCT05819060 · Fudan University
2023-04-30 – 2025-03-30 · Recurrent Ovarian Cancer
What this study did
NCT04828395 · Tianjin Medical University Cancer Institute and Hospital
2021-03-01 – 2025-03-01 · Non-small Cell Lung Cancer
What this study did
NCT05085626 · Tianjin Medical University Cancer Institute and Hospital
2021-02-08 – 2024-12-31 · Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer
What this study did
NCT05938374 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2023-05-01 – 2024-12-31 · Soft Tissue Sarcoma
What this study did
NCT04517357 · Jiangsu HengRui Medicine Co., Ltd.
2020-10-16 – 2024-11-01 · Relapsed Ovarian Cancer
What this study did
NCT05170594 · The Second Affiliated Hospital of Shandong First Medical University
2021-12-24 – 2024-06-30 · Ovarian Cancer
What this study did
NCT05732129 · Fudan University
2023-03-01 – 2023-12-31 · Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer
What this study did
NCT05223582 · Fudan University
2021-05-01 – 2023-12 · High-risk Prostate Cancer, Neoadjuvant Therapy
What this study did
NCT04535687 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
2020-12-17 – 2023-06-12 · Renal Cell Carcinoma
What this study did
Phase 1/2 (8)
Other / comorbidity
NCT07141771 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-12-31 – 2030-12-31 · SCLC, Extensive Stage
What this study did
NCT05983237 · Jun Guo
2023-08-15 – 2027-12-31 · Melanoma
What this study did
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT05928780 · Fudan University
2023-07-01 – 2025-09-01 · TNBC - Triple-Negative Breast Cancer
What this study did
NCT04518501 · Xing Xie
2020-07-01 – 2025-01-01 · Efficacy and Safety
What this study did
NCT04228601 · Jiangsu HengRui Medicine Co., Ltd.
2020-01-21 – 2023-01-15 · Advanced Pancreatic Cancer
What this study did
NCT04659785 · Tianjin Medical University Second Hospital
2020-07-01 – 2022-12-31 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT04400188 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-11 – 2022-01-15 · Small Cell Lung Cancer
What this study did
Phase 1 (24)
Other / comorbidity
NCT04694365 · Jiangsu HengRui Medicine Co., Ltd.
2021-03-01 – 2024-06-19 · Hepatic Impairment, Healthy Subjects
What this study did
NCT05032235 · Jiangsu HengRui Medicine Co., Ltd.
2021-11-09 – 2023-12-05 · Renal Impairment
What this study did
NCT04425876 · Jiangsu HengRui Medicine Co., Ltd.
2020-12-17 – 2023-09-01 · Pancreatic Cancer
What this study did
NCT04718740 · Jiangsu HengRui Medicine Co., Ltd.
2021-06-25 – 2023-07-15 · Recurrent Ovarian Cancer
What this study did
NCT04108247 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-26 – 2023-06 · Prostate Cancer Castration-resistant Prostate Cancer
What this study did
NCT05440006 · Jiangsu HengRui Medicine Co., Ltd.
2022-07-03 – 2022-07-20 · Solid Tumor
What this study did
NCT03075462 · Jiangsu HengRui Medicine Co., Ltd.
2017-03-09 – 2021-12-13 · Ovarian Cancer, Triple Negative Breast Cancer
What this study did
NCT04041011 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-17 – 2021-04-23 · Small Cell Lung Cancer
What this study did
NCT03945604 · Jiangsu HengRui Medicine Co., Ltd.
2019-06-04 – 2021-02-09 · Triple Negative Breast Cancer
What this study did
NCT04341077 · Jiangsu HengRui Medicine Co., Ltd.
2020-04-10 – 2020-10-20 · Healthy Adult Male and Female Volunteers
What this study did
NCT03509636 · Jiangsu HengRui Medicine Co., Ltd.
2018-04-04 – 2020-07-23 · Ovarian Cancer
What this study did
NCT04333134 · Atridia Pty Ltd.
2020-04-17 – 2020-06-30 · Healthy Volunteers
What this study did
NCT02747342 · Atridia Pty Ltd.
2016-09 – 2020-06-28 · Neoplasm, Prostate Cancer
What this study did
NCT03645200 · Tianjin Medical University Second Hospital
2019-07-01 – 2020-06-01 · Advanced Cancer
What this study did
NCT04013048 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-08 – 2019-12-24 · Solid Tumor
What this study did
NCT04108676 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-07 – 2019-11-18 · Advanced Solid Tumor
What this study did
NCT04011124 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-24 – 2019-09-16 · Healthy Male Subjects
What this study did
NCT04193319 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-19 – 2019-09-12 · Advanced Cancer
What this study did
NCT04521192 · Jiangsu HengRui Medicine Co., Ltd.
2019-05-06 – 2019-09-05 · Healthy Adult Subjects
What this study did
NCT03182673 · Jiangsu HengRui Medicine Co., Ltd.
2017-07-24 – 2019-06-12 · Solid Tumor
What this study did
NCT02759666 · Atridia Pty Ltd.
2016-06-01 – 2019-04-26 · Neoplasm, Solid Tumors
What this study did
NCT03026881 · Jiangsu HengRui Medicine Co., Ltd.
2017-01 – 2018-06 · Recurrent and Metastatic Gastric Cancer
What this study did
NCT02575651 · Jiangsu HengRui Medicine Co., Ltd.
2015-04 – 2018-06 · Advanced Solid Malignancies
What this study did
NCT03062982 · Jiangsu HengRui Medicine Co., Ltd.
2016-12-21 – 2017-01-04 · Solid Tumor
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT04782089 · Qilu Hospital of Shandong University
2021-05-06 – 2024-06-01 · Small Cell Lung Cancer
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT06533384 · Guangdong Provincial People's Hospital
2024-08-01 – 2030-12-31 · Triple-negative Breast Cancer
What this study did

Competitive landscape

This drug's own stage for Metastatic Castration-Resistant Prostate Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Fluzoparib: this drugPhase 3Small moleculePARP (poly ADP-ribose polymerase), specifically PARP-1not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
OlaparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
RucaparibApprovedSmall moleculePARP (poly ADP-ribose polymerase) enzymes, PARP1/2Partial signalNo reviewed efficacy summary in this indication
TalazoparibApprovedSmall moleculePARPnot yet gradedNo reviewed efficacy summary in this indication
Elfetabart DrozuntecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
HRS-4357Phase 3UndisclosedPSMAnot yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
MevrometostatPhase 3Small moleculeEZH2not yet gradedNo reviewed efficacy summary in this indication
OpevesostatPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
PasritamigPhase 3Multispecific antibody—not yet gradedNo reviewed efficacy summary in this indication
Zadavotide GuraxetanPhase 3Radioconjugate (actinium-225)PSMAnot yet gradedNo reviewed efficacy summary in this indication
LuxdegalutamidePhase 2Small moleculeAndrogen receptor, Androgen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
ABBV-969Phase 1UndisclosedPSMA / STEAP1not yet gradedNo reviewed efficacy summary in this indication
AKY-2519Phase 1RadiopharmaceuticalB7-H3-targeted radioligand therapynot yet gradedNo reviewed efficacy summary in this indication
BPX-601Phase 1Cell therapyPSCAnot yet gradedNo reviewed efficacy summary in this indication
RG6852
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(20 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Fluzoparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
Phase 1/2MelanomaRecruiting
Est. primary completion 2026-12-31 · NCT05983237 · CT.gov ↗
What to watch
Phase 3Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04691804 · CT.gov ↗
What to watch
2027 (8)
February 2027 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
April 2027 (2)
Phase 2Ewing SarcomaRecruiting
Est. primary completion 2027-04 · NCT06827717 · CT.gov ↗
What to watch
Phase 2Germline BRCA-mutated HER2-negative Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05576389 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-06-20 · NCT07033819 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Metastatic Castration-Resistant Prostate CancerRecruiting
Est. primary completion 2027-10-30 · NCT06971211 · CT.gov ↗
What to watch
Phase 3Breast Cancer MetastaticActive not recruiting
Est. primary completion 2027-10-30 · NCT06612814 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Platinum-sensitive, TNBC, Triple Negative Breast Cancer, BRCA1/2 Mutation or NotRecruiting
Est. primary completion 2027-11-30 · NCT07321015 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
2028 (4)
May 2028 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-05-31 · NCT05891093 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Triple-Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2028-07-30 · NCT07752550 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2028-12-30 · NCT07355010 · CT.gov ↗
What to watch
Phase 2Sarcoma,Soft Tissue, Brachytherapy, Poly(ADP-ribose) Polymerase InhibitorsRecruiting
Est. primary completion 2028-12-31 · NCT05894018 · CT.gov ↗
What to watch
2030 (3)
May 2030 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2030-05-01 · NCT06954584 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2SCLC, Extensive StageNot yet recruiting
Est. primary completion 2030-06-30 · NCT07141771 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07382713 · CT.gov ↗
What to watch
2031 (3)
February 2031 (1)
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2031-02-28 · NCT07647653 · CT.gov ↗
What to watch
March 2031 (1)
Phase 3Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast CancerRecruiting
Est. primary completion 2031-03 · NCT06255392 · CT.gov ↗
What to watch
December 2031 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07353437 · CT.gov ↗
What to watch

See the full readout calendar ↗